The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Open accessAbstract
Peroxisome proliferator-activated receptor delta (PPARδ), a member of the nuclear receptor family, is emerging as a key metabolic regulator with pleiotropic actions on various tissues including fat, skeletal muscle, and liver. Here we show that the PPARδ agonist KD3010, but not the well-validated GW501516, dramatically ameliorates liver injury induced by carbon tetrachloride (CCl(4)) injections. Deposition of extracellular matrix proteins was lower in the KD3010-treated group than in the vehicle- or GW501516-treated group. Interestingly, profibrogenic connective tissue growth factor was induced significantly by GW501516, but not by KD3010, following CCl(4) treatment. The hepatoprotective and antifibrotic effect of KD3010 was confirmed in a model of cholestasis-induced liver injury and fibrosis using bile duct ligation for 3 wk. Primary hepatocytes treated with KD3010 but not GW501516 were protected from starvation or CCl(4)-induced cell death, in part because of reduced reactive oxygen species production. In conclusion, our data demonstrate that an orally active PPARδ agonist has hepatoprotective and antifibrotic effects in animal models of liver fibrosis, suggesting a possible mechanistic and therapeutic approach in treating patients with chronic liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, PPAR-δ agonists have been insufficiently characterized in clinical studies and were mostly tested as single PPAR-δ agonists in experimental animal models, where they demonstrated almost no impact on liver injury improvement, shifting the focus on dyslipidemia studies or studies regarding metabolic disorders.[147]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [147]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Another study using the PPAR-δ agonist KD3010 demonstrated an amelioration of liver injury in a CCl 4 mouse model, which was confirmed by a study showing further anti-fibrotic effects after bile duct ligation in mice.[147]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [147]
The cited source says what the claim attributes to it.
In the citing paper
“Another study using the PPAR-δ agonist KD3010 demonstrated an amelioration of liver injury in a CCl 4 mouse model, which was confirmed by a study showing further anti-fibrotic effects after bile duct ligation in mice.[147]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Self-citationMacrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Bataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
AMPK and PPARδ Agonists Are Exercise Mimetics
Narkar, V. A., Downes, M., Yu, R. T., Embler, E., Wang, Y.-X., Banayo, E., Mihaylova, M. M., Nelson, M. C., Zou, Y., Juguilon, H., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.051 · Cited by 1,222
Self-citationPoynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M., & Albrecht, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.33023 · Cited by 1,146
Oliver, W. R., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091021198 · Cited by 1,046
Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Red Eagle, A., Vats, D., Morel, C. R., Goforth, M. H., Subramanian, V., Mukundan, L., Ferrante, A. W., & Chawla, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.04.003 · Cited by 847
Kang, K., Reilly, S. M., Karabacak, V., Gangl, M. R., Fitzgerald, K., Hatano, B., & Lee, C.-H. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.04.002 · Cited by 699
PPAR : a dagger in the heart of the metabolic syndrome
Barish, G. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27955 · Cited by 641
PPARδ regulates glucose metabolism and insulin sensitivity
Lee, C.-H., Olson, P., Hevener, A., Mehl, I., Chong, L.-W., Olefsky, J. M., Gonzalez, F. J., Ham, J., Kang, H., Peters, J. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511253103 · Cited by 497
Self-citation
Research works printed but not linked: 2
- B Schnabl, D Scholten, DA Brenner, What is the potential role of antifibrotic agents for the treatment of liver disease? Nat Clin Pract Gastroenterol Hepatol 5, 496–497 (2008). · DOI
- M Downes, et al., A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 11, 1079–1092 (2003). · DOI · Paper page
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Self-citationLiver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
Self-citationLiver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,160
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease
Duan, Y., Llorente, C., Lang, S., Brandl, K., Chu, H., Jiang, L., White, R. C., Clarke, T. H., Nguyen, K., Torralba, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1742-x · Cited by 844
Self-citation
Metadata
- Authors
- Iwaisako, K., Haimerl, M., Paik, Y.-H., Taura, K., Kodama, Y., Sirlin, C., Yu, E., Yu, R. T., Downes, M., Evans, R. M., Brenner, D. A., & Schnabl, B.
- Affiliations
- University of California San Diego (US)
- Departments of aMedicine and
- Samsung Medical Center (KR)
- Salk Institute for Biological Studies (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2012-04-25
- Volume
- 109
- Issue
- 21
- Pages
- E1369-76
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3361396
- OpenAlex
- W2105900654
- Cited by
- 157
- References
- 24
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 9 · 2023: 9 · 2022: 6 · 2021: 10 · 2020: 18 · 2019: 10 · 2018: 13 · 2017: 14 · 2016: 13 · 2015: 11 · 2014: 9 · 2013: 16 · 2012: 3
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Japan Society for the Promotion of Science (22590728, 23659647, 23390322)
- National Institute on Alcohol Abuse and Alcoholism (R01AA020703)
- National Cancer Institute (P30CA014195)
- National Institute of General Medical Sciences (R01GM041804)
- National Institute of Diabetes and Digestive and Kidney Diseases (R24DK080506, R37DK057978, DK 080506, R01DK057978, R01DK072237, R24DK090962, K08DK081830)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD000850)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- PPARδ agonist, GW501516, liver fibrosis, hepatoprotection, carbon tetrachloride-induced liver injury, bile duct ligation, cholestasis, connective tissue growth factor, extracellular matrix deposition, reactive oxygen species, hepatocyte death, chronic liver disease
- MeSH terms
- Animals, Carbon Tetrachloride, Cells, Cultured, Disease Models, Animal, Kupffer Cells, Liver Cirrhosis, Male, Mice, Inbred C57BL, Piperazines, Sulfonamides, Thiazoles, Hepatocytes, PPAR delta, Mice, Hepatic Stellate Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. https://app.cochat.ai/papers/10.1073/pnas.1202464109
- The paper
- Iwaisako, K., Haimerl, M., Paik, Y.-H., Taura, K., Kodama, Y., Sirlin, C., Yu, E., Yu, R. T., Downes, M., Evans, R. M., Brenner, D. A., & Schnabl, B. (2012). Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1202464109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.